Arcus Q2 Revenue Plunges on License Income Drop, Guides 2026 Revenue to $65M-$75M
RCUS has more than doubled off its 52-week low of $8.88.
Summary
Arcus Biosciences reported a sharp Q2 revenue decline driven by a drop in license income, posting a $91 million net loss. The company guided 2026 GAAP revenue to $65-$75 million and expects to end the year with about $600 million in cash, providing runway into 2028. This follows a Q1 revenue decline and the discontinuation of two clinical trials, though R&D expenses are down as late-stage programs wind down. The cash position remains solid, but the revenue trajectory and ongoing losses will pressure the stock. Watch for updates on the casdatifan collaboration with Summit and any new partnership revenue.
At the time of this announcement, RCUS was trading at $28.04 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $8.88 to $31.74. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.